Table 3.
Novel approaches and strategies for subunit erysipelas vaccines.
| Vaccine type | Antigena | Expression vector | Adjuvant | Challenge serovar | Species | Number (route)b | Survival | References |
|---|---|---|---|---|---|---|---|---|
| Subunit | SpaA | E. coli | Whole E. coli cells | 2 (Tama-96) | Mice | 10 (IP) | 100% | (89) |
| Subunit | SpaA | E. coli | 1a (Fujisawa) | Mice | 5 (SC) | 100% | (90) | |
| 5 (IP) | 100% | |||||||
| Subunit | SpaA | E. coli | Freund's adjuvant | 1a (Fujisawa) | Pigs | 4 (IM) | 100% | (122) |
| 2b (82–875) | 2 (IM) | 100% | ||||||
| Subunit | SpaA | Bacillus brevis | E. coli heat-labile enterotoxin | 1a (Fujisawa) | Pigs | 6 (IN) | 100% | (151) |
| Subunit | CbpB | E. coli | Freund's adjuvant | 1a (Fujisawa) | Mice | 10 (IM) | 80% | (131) |
| Pigs | 7 (IM) | 86% | ||||||
| Subunit | GAPDH | E. coli | Freund's adjuvant | 1a (SE38) | Mice (C57BL/6) | 10 (IP) | 100% | (152) |
| HP0728 | 10 (IP) | 0% | ||||||
| HP1472 | 10 (IP) | 0% | ||||||
| CbpB-N | 10 (IP) | 50% | ||||||
| SpaA | 10 (IP) | 100% | ||||||
| None (PBS) | 10 (IP) | 0% | ||||||
| GAPDH | E. coli | Montanide ISA 206 | 1a (SE38) | Pigs | 5 (SC) | 80% | ||
| SpaA | 5 (SC) | 100% | ||||||
| None (PBS) | 5 (SC) | 0% | ||||||
| Subunit | Soluble CBD-SpaA | E. coli | None | 15 | Mice | 8 (SC) | 75% | (153) |
| Coated CBD-SpaA | Avicelc | 8 (SC) | 100% | |||||
| ERT2T-A containing whole bacterin | None | 8 (SC) | 62.5% | |||||
| None (PBS) | None | 8 (SC) | 0% |
a
SpaA, surface protective antigen A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CbpB, choline-binding protein B; PBS, Phosphate-buffered saline; CBD, cellulose-binding domain.
b
Administration route: IP, intraperitoneal; SC, subcutaneous; IM, intramuscular; IN, intranasal.
c
Micro-crystalline cellulose.